Review Article
Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges
Table 1
Ongoing or recently completed clinical trials of a few liposomal nanoformulations used for cancer chemotherapy
.
| Trade name/composition | Indication | Phase | Stage |
|
PEGylated Liposomal Doxorubicin | AIDS-associated non-Hodgkin’s lymphoma | I | Completed | Doxil/CAELYX Liposomal Doxorubicin | Malignant female reproductive system neoplasm, Ovarian cancer | I | Active | Doxil Liposomal Doxorubicin | Resistant solid malignancies | I | Completed | Liposomal Cytarabine | Central nervous system malignancies, Stage IV breast cancer | II | Active | Liposomal Entrapped Paclitaxel Easy to Use (LEP-ETU) | Advanced cancer | I | Completed | Liposomal Daunorubicin | Hematologic cancer, Chronic myelomonocytic leukemia previously treated Myelodysplastic syndromes and recurrent adult Acute myeloid leukemia | II | Completed | BLP25 Liposome Vaccine | Lung neoplasms Non-small-cell lung carcinoma | II | Completed | CPX-351 Liposomal Cytarabine-Daunorubicin | Acute myeloid leukemia | I | Active | Liposomal Vincristine | Acute lymphoblastic leukemia | II | Active | Liposomal LE-SN38 | Advanced cancer | I | Completed | IHL-305 Irinotecan Liposome Injection | Advanced solid tumours | I | Active | Liposome Encapsulated Mitoxantrone (LEM) | Advanced cancer | I | Completed | Liposomal Encapsulated Docetaxel (LE-DT) | Advanced solid tumours | I | Completed |
|
|
Data retrieved from US National Institutes of Health website (http://clinicaltrials.gov/) on August 21, 2013.
|